Benoît van den Hove tells Euractiv that scaling biotech companies at a global level still depends on capital that Europe does not yet mobilise at sufficient scale
Belgium’s biotech sector is often seen as proof that Europe can turn scientific strength into global success. But even in one of Europe’s most advanced ecosystems, scaling required access to capital beyond national markets.
In a sector where success depends on sufficient, even abundant capital, Europe still lacks the depth, integration and speed required to finance growth at scale. As the EU advances its Biotech Act alongside efforts to deepen capital markets, the focus is shifting. The issue is no longer innovation, but whether Europe has the financial firepower to match it.
Euractiv spoke with stock exchange operator Euronext Brussels CEO Benoît van den Hove about what Belgium’s experience reveals, and what Europe still needs to fix.
NV: What’s the main challenge of Belgium’s biotech companies?
